Clinical Trial Update: A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for S227928 as a single agent and in combination with Venetoclax in relapsed/refractory AML, MDS/AML, and CMML shows the study (Phase 1/2)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• S227928
• Venetoclax (venetoclax)

Snippet

Sponsor: Servier Bio-Innovation LLC | Conditions: Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1, Phase 2 | Status: TERMINATED